Triazolopiridina refers to compounds of formula (i) wherein R1 is optionally substituted aryl or heteroaryl alkyl with R6 (C1 - C6), R6 - alkoxy (C1 - C6), R6 - ((C1 - C6) - alkoxy alkyl (C1 - C6) -, - C (= or R6), among others, Where R6 (C3 C6) cycloalkyl, aryl, heterocicloalquilo 3-10 m Member, among others R2 is optionally substituted aryl or heteroaryl Halo, hydroxyl, NS,Alkyl (C1 - C6), among others R3 is H, halogen, Hydroxy, amino, alkoxy (c1-c4), among others R4 is H, CN, Hydroxy alkyl (c1-c4), alquinilo (C2 - C6), among others R5 is H.Preferred compounds are: 2 - 2-cyclopropyl-1 - N - [4 - (2 - {[2 - methoxy - 3 - ((4 - ilcarbonil) phenyl] amino} [1,2,4] triazolo [1,5-a] pyridin-3 (IL - 6) phenyl] acetamide n - (4 - (2 - ciclopropilmetil) - {[2 - (4 - methoxy - (4 - ilcarbonil) phenyl] amino} [1,2,4] triazolo [1,5-a] pyridin-3 (IL - 6) benzamide, N - [4 - (2 - ((4 - (1 - ilcarb azetidin - Onil) - 2-methoxyphenyl] amino} [1,2,4 triazolo [1],5] pyridin-3 (IL - 6) phenyl] - 2 - (4-fluorophenyl) acetamide among others. It also relates to a preparation method and a Pharmaceutical composition. These compounds are inhibitors of the monopolar Spindle kinase 1 (- 1) to be useful in the treatment of Leukemia, malignant lymphoma, sarcomaSE REFIERE A COMPUESTOS DERIVADOS DE TRIAZOLOPIRIDINA DE FORMULA (I) DONDE R1 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO CON R6-ALQUIL(C1-C6), R6-ALCOXI(C1-C6), R6-(ALCOXI(C1-C6)-ALQUIL(C1-C6))-O-, -C(=O)R6, ENTRE OTROS, EN DONDE R6 ES CICLOALQUILO(C3-C6), ARILO, HETEROCICLOALQUILO DE 3 A 10 MIEMBROS, ENTRE OTROS R2 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO CON HALO, HIDROXILO, CN, ALQUILO(C1-C6), ENTRE OTROS R3 ES H, HALOGENO, HIDROXI, AMINO, ALCOXI(C1-C4), ENTRE OTROS R4 ES H, CN, HIDROXI-ALQUILO(C1-C4), ALQUINILO(C2-C6), ENTRE OTROS R5 ES H. SON COMPUESTOS PREFERIDOS: 2-CICLOPROPIL-N-[4-(2-{[2-METOXI-4-(MORFOLIN-4-ILCARBONIL)FENIL]AMINO}[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL)FENIL]ACETAMIDA N-(CICLOPROPILMETIL)-4-(2-{[2-METOXI
